Yearly Archives: 2009
Phase IIa clinical data confirms potential of Allon’s davunetide as a treatment for cognitive impairment in schizophrenia patients
VANCOUVER — December 7, 2009 - Allon Therapeutics Inc. (TSX: NPC) announced today that the results of a Phase IIa clinical trial presented at a major scientific meeting indicate that the Company’s lead neuroprotective drug candidate davunetide achieved measurable positive treatment effects in... Continue reading
Posted in News Releases
Allon chosen as “Top 10 Partnering Candidate” and presenting at major partnership conference
VANCOUVER — November 17, 2009 - Allon Therapeutics Inc. (TSX: NPC) announced today its lead drug candidate, davunetide, has been selected as one of the Top 10 partnership candidates by a leading industry expert. The 2009 Windhover Therapeutic Areas Partnership Conference features the Top 10 ... Continue reading
Posted in News Releases
Allon Therapeutics releases Third Quarter operating results
VANCOUVER — November 10, 2009 - Allon Therapeutics Inc. (TSX: NPC) continues to advance its Phase II clinical program to develop lead product davunetide as the first effective treatment for a number of brain disorders broadly categorized as frontotemporal dementia (FTD), the Company reported toda... Continue reading
Posted in News Releases
Canadian patent strengthens IP for Allon’s 2nd technology platform
VANCOUVER — October 29, 2009 - Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s business progress at two upcoming investment and partnering conferences attended by public and private equity investors, research analysts, investment banke... Continue reading
Posted in News Releases
Canadian patent strengthens IP for Allon’s 2nd technology platform
VANCOUVER — October 8, 2009 - Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a Canadian patent covering the chemical composition of the Com... Continue reading
Posted in News Releases